However, higher levels of p53 autoantibodies have been mainly associated with a worst prognosis of the disease than with an early stage of BC and to many different cancers, as well as NY-ESO-1 autoantibodies, and thus, the individual measurement of these autoantibodies in plasma or serum is not enough for the specific diagnosis of BC. This evidence concerns the gene TP53 and breast cancer.